2-pentyl-1,4-butanediol | 55881-93-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-pentyl-1,4-butanediol
• 英文别名: 2-Pentylbutane-1,4-diol
• CAS: 55881-93-1
• 化学式: C₉H₂₀O₂
• 分子量: 160.257
• InChiKey: VXSKDBUGBVRCQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-pentyl-1,4-butanediol 、 甲氧基-三氟甲基苯 以37%的产率得到
  参考文献：
  名称：

  通过ALET不对称烯烃cycloalumination 3，催化用neomenthylindenyl锆η 5 -complexes

  摘要：

  纸张致力于末端烯烃cycloalumination的反应通过ALET研究3（对具有neomenthylindenyl锆络合物催化小号）（对小号） -双[ η 5 - [1 - [（1小号，2小号，5 [R）-2-异丙基-5- methylcycloh-exyl]茚基]二氯化锆（1）或（对小号） - （η 5 -环戊二烯基）[ η 5 - [1 - [（1小号，2小号，5 R）-2-异丙基-5-甲基环己基]茚基]]二氯化锆（2）。结果表明，烯烃和催化剂的结构以及溶剂影响了反应产物3-烷基取代的氧化铝环戊烷的总产率和对映体过量。在烃类溶剂中，末端烯烃与配合物1催化的AlEt 3的反应主要产生环状有机铝化合物的S-对映异构体，其对映体过量最高可达37％。配合物2显示较小的立体诱导作用，并提供具有6–26％ee的氧化铝环戊烷的R对映异构体。 显示了含硒的衍生试剂（R）-2-苯基硒基丙酸对由环状有机铝化合物制得的β-烷基-1

  DOI：

  10.1016/j.jorganchem.2012.10.021
• 作为产物：
  描述：

  1-庚烯 、 三乙基铝 在 bis(1-(-)-neomenthylindenyl)zirconium dichloride 、 氧气 作用下， 以 二氯甲烷 为溶剂， 反应 50.0h， 以60%的产率得到
  参考文献：
  名称：

  Catalytic enantioselective ethylalumination of terminal alkenes: substrate effects and absolute configuration assignment

  摘要：

  The chemo- and enantioselectivity of the reaction of alkenes with AlEt3 catalyzed by bis(1-neomenthyl-indenyl)zirconium dichloride has been studied. The reaction with linear alkenes in a chlorinated solvent (CH2Cl2) gives mainly carbometallation products in 70-80% yield and with enantiomeric purity of 47-70%ee with an (S)-configuration. In the case of vinylcycloalkanes and styrene, the reaction provides roughly equal amounts of carbometallation products and substituted alumolanes with enantioselectivities of 39-69%ee and 40-57%ee, respectively.(R)-MTPA and (R)-2-phenylselenopropionic acid [(R)-PSPA] were used as the derivatization reagents for enantiomeric excess estimation and the absolute configuration assignment of beta-chiral primary alcohols and 2-substituted 1,4-butanediols resulting from oxidation and hydrolysis of the organoaluminum products. It was shown that the specific rotation changes sign in the series of enantiomerically enriched 2-ethyl-1-alkanols when going from beta-ethyl-substituted octanol to nonanol. The conformational analysis of the MTPA and PSPA esters of 2-ethyl-1-alkanols was performed and a dependence of their conformational composition on the type of substituent at the beta-stereogenic center was established. Calculation of the Se-77 NMR chemical shifts of the possible conformers of the PSPA esters demonstrated that the conformation of the selenium moiety has the most pronounced effect on the delta(Se) value. The high efficiency of PSPA application for the enantiomeric purity estimation and the absolute configuration assignment of 2-ethyl-1-alkanols is shown. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2014.11.019

文献信息

• IDO INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160289171A1

  公开（公告）日：2016-10-06

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  已披露的化合物可调节或抑制吲哌酮胺2,3-二氧化酶（IDO）的酶活性，含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病，如癌症、病毒感染和/或炎症性疾病的方法。
• INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20200069646A1

  公开（公告）日：2020-03-05

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.

  披露了调节或抑制吲哚胺2,3-双加氧酶（IDO）酶活性的化合物，包含所述化合物的药物组合物以及使用本披露的化合物治疗增殖性疾病的方法，如癌症、病毒感染和/或炎症性疾病。
• Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
  申请人：Gomtsyan Arthur

  公开号：US20060128689A1

  公开（公告）日：2006-06-15

  Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A 1 , A 2 , A 3 , A 4 , R 7 , R 8 , R 9 , X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

  对VR1受体拮抗剂，其化学式为(I)或其药用可接受的盐、前药或前药的盐，其中A1、A2、A3、A4、R7、R8、R9、X、Y、Z、L、n和m的定义如本文所述，并且在通过抑制VR1受体预防或改善的疾病中具有用处。
• COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
  申请人：AstraZeneca AB

  公开号：US20140206677A1

  公开（公告）日：2014-07-24

  Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.

  化合物的结构式（I），其药学上可接受的盐，以及利用该结构式（I）化合物治疗细菌感染的用途被披露。
• Hiv Integrase Inhibitors
  申请人：Morrissette Matthew M.

  公开号：US20080139579A1

  公开（公告）日：2008-06-12

  Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  化合物I的结构是HIV整合酶的抑制剂和HIV复制的抑制剂：（I）其中Z，R1，R2，R3，R4，R5，R6，R7，R8和R9在此处定义。这些化合物对预防和治疗HIV感染以及预防、延迟AIDS的发作和治疗非常有用。这些化合物可作为化合物本身或作为药学上可接受的盐的形式用于对抗HIV感染和AIDS。这些化合物及其盐可作为药物组合物的成分使用，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。